Updated August 2026. Operating a compounding pharmacy laboratory in the UAE requires compliance with a specialised licensing and quality framework administered by the Ministry of Health and Prevention (MOHAP), the Dubai Health Authority (DHA), and—for facilities operating in Dubai Healthcare City—by the DHCC regulatory body. UAE compounding pharmacy regulations align with internationally recognised standards including USP Chapters 795 (non-sterile), 797 (sterile), and 800 (hazardous drugs), making the UAE one of the more rigorous compounding pharmacy regulatory environments in the GCC region. Understanding the specific licence categories, pharmacist staffing requirements, bulk API import rules, and the distinction between sterile and non-sterile compounding is essential for any investor, pharmacist group, or hospital operator entering this specialised segment.
- MOHAP compounding pharmacy licence costs AED 15,000–40,000 in initial fees, with DHA compounding licence adding AED 10,000–25,000 for Dubai-based operations.
- Total setup investment for a compliant compounding pharmacy lab ranges from AED 40,000 to AED 120,000 in regulatory and fitout costs, exclusive of cleanroom construction and equipment.
- Sterile compounding (IV admixtures, eye drops, injectables) requires a Class ISO 5 cleanroom within a Class ISO 7 buffer zone, adding substantial construction cost above non-sterile operations.
- Bulk active pharmaceutical ingredient (API) import for compounding requires a separate MOHAP controlled substances or general API import permit per substance.
- A minimum of two licensed pharmacists—including one designated Pharmacist-in-Charge—is mandatory for all MOHAP-licensed compounding pharmacy operations.
Overview of the UAE Compounding Pharmacy Market
Pharmaceutical compounding—the preparation of customised medications for individual patients when commercially available products are unsuitable, unavailable, or in the wrong dosage form—serves a critical healthcare need in the UAE. Key applications include paediatric dosage forms (liquid suspensions for children who cannot swallow tablets), customised hormone replacement therapy (HRT) preparations, dermatology formulations (customised topical creams and ointments), veterinary compounding, and specialty sterile preparations for oncology and ophthalmology.
The UAE compounding pharmacy market is served by a relatively small number of specialist compounding labs, several of which operate in Dubai Healthcare City under DHA-DHCC dual licensing. Hospitals with high volumes of oncology patients or paediatric cases often establish in-house hospital pharmacy compounding units to meet patient-specific needs for chemotherapy admixtures, parenteral nutrition, and sterile ophthalmic preparations. The distinction between patient-specific compounding and manufacturing (producing batches without a specific patient prescription) is critical in UAE regulation: only the former is permitted under a compounding pharmacy licence.
MOHAP and MOH Compounding Pharmacy Licensing
MOHAP issues the Compounding Pharmacy Licence for facilities in the Northern Emirates (Sharjah, Ajman, UAQ, Fujairah, Ras Al Khaimah) and for federal-level compliance. The MOHAP compounding pharmacy licence is distinct from a standard retail pharmacy licence and requires a separate application, facility inspection, and quality standards compliance package. Initial MOHAP licence fees range from AED 15,000 to AED 40,000 depending on the scope of compounding (non-sterile, sterile, or hazardous drugs). Annual renewal fees are AED 8,000–20,000.
In Dubai, the DHA issues a Compounding Pharmacy Permit as an endorsement on the standard pharmacy licence. DHA compounding permit fees add AED 10,000–25,000 to the base pharmacy licence cost. The DHA permit application requires submission of standard operating procedures (SOPs) for all compounding processes, a master formulary documenting each compounded preparation, equipment calibration records, and stability testing protocols. In Abu Dhabi, DOH issues an equivalent compounding endorsement on the pharmacy licence, with comparable requirements and fees.
GMP Compounding Standards: USP 795, 797, and 800
MOHAP and DHA both formally reference the United States Pharmacopeia (USP) compounding chapters as the applicable quality standards for UAE compounding pharmacies. USP Chapter 795 covers non-sterile pharmaceutical compounding, addressing environmental controls, component quality, formula documentation, and stability assessment for preparations such as capsules, oral solutions, topical creams, and suppositories. UAE regulators expect non-sterile compounding labs to maintain temperature-controlled work areas, calibrated weighing equipment, and documented beyond-use dating (BUD) protocols consistent with USP 795.
USP Chapter 797 is the governing standard for sterile compounding, mandating ISO-classified cleanroom environments (ISO 5 primary engineering controls within ISO 7 buffer rooms), garbing protocols, fingertip and surface media-fill testing, and rigorous environmental monitoring programmes including viable and non-viable particle sampling. Compliance with USP 797 (2023 revision, which UAE regulators use as the current reference) requires significantly greater capital investment than non-sterile compounding, primarily driven by cleanroom construction and certification costs. A compliant sterile compounding suite in a UAE pharmacy can cost AED 200,000–600,000 in construction and equipment alone.
USP Chapter 800 applies to compounding facilities that handle hazardous drugs—primarily antineoplastic chemotherapy agents, certain hormones, and antiviral drugs. USP 800 requires designated containment primary engineering controls (C-PECs such as Biological Safety Cabinets Class II B2 or Compounding Aseptic Containment Isolators), negative-pressure buffer rooms, closed-system drug transfer devices (CSTDs), and specific disposal protocols for hazardous waste. UAE hospitals compounding oncology preparations must meet USP 800 requirements and notify DHA or DOH of hazardous drug compounding activities.
Sterile Versus Non-Sterile Compounding: Facility Requirements
The regulatory and investment distinction between sterile and non-sterile compounding is substantial. Non-sterile compounding—capsules, topical preparations, oral solutions, rectal and vaginal formulations—can be conducted in a controlled temperature and humidity environment without full cleanroom classification. A compliant non-sterile compounding lab requires calibrated balances, a laminar flow hood for operations requiring dust control, a dedicated compounding area segregated from dispensing areas, and temperature-controlled storage. Setup costs for a non-sterile compounding area within an existing pharmacy run AED 30,000–80,000 in equipment and fitout, with MOHAP regulatory fees adding AED 15,000–40,000.
Sterile compounding—IV admixtures, ophthalmic drops, injectables, parenteral nutrition—requires ISO-classified cleanrooms, continuous environmental monitoring, and personnel competency programmes including aseptic technique assessment and media-fill validation. Full sterile compounding suite construction (cleanroom, HVAC, monitoring systems, laminar flow hoods or isolators) costs AED 300,000–800,000. The total regulatory and infrastructure investment for a standalone sterile compounding pharmacy in the UAE typically ranges from AED 500,000 to AED 1.5 million.
Bulk API Import Permits and Controlled Substance Regulations
The import of bulk active pharmaceutical ingredients (APIs) for compounding purposes in the UAE requires specific import authorisation from MOHAP’s Drug Control Department. APIs classified as controlled substances under the UAE Federal Law No. 14 of 1995 on Narcotics and Psychotropic Substances—including opioids, benzodiazepines, amphetamines, and certain hormones—require a separate MOHAP Controlled Substances Import Permit per shipment, in addition to the general API import documentation.
All APIs used in UAE compounding pharmacies must be sourced from MOHAP-registered pharmaceutical-grade suppliers. The use of non-pharmaceutical grade chemicals or unregistered API sources is a serious regulatory violation. MOHAP’s Drug Control inspectors review compounding pharmacy API purchasing records during facility inspections and may confiscate non-compliant materials. API import permits require submission of a Certificate of Analysis (CoA), GMP manufacturing certificate of the API manufacturer, and documentation of the specific compounded preparations for which the API will be used. MOHAP issues import permits per batch; pharmacies with high compounding volumes may apply for blanket import authorisation for frequently used APIs.
Pharmacist-in-Charge and Staffing Requirements
MOHAP and DHA both mandate a minimum of two licensed pharmacists for any compounding pharmacy operation. One pharmacist must be formally designated as the Pharmacist-in-Charge (PIC) and must be registered with the relevant authority (DHA or MOHAP) in the PIC role. The PIC bears regulatory responsibility for all compounding activities, quality standards compliance, controlled substances records, and staff training. The second licensed pharmacist provides operational coverage and serves as the designated deputy during PIC absence.
For sterile compounding operations, DHA and MOHAP additionally require all pharmacists and pharmacy technicians involved in aseptic compounding to complete documented aseptic technique training, pass initial and annual media-fill tests, and receive annual competency assessments in garbing, cleanroom behaviour, and environmental monitoring interpretation. DHA may require compounding pharmacists to hold additional certification such as the Board of Pharmacy Specialties (BPS) Compounded Sterile Preparations certification, particularly for facilities compounding high-risk sterile preparations.
DHCC Specialty Compounding and Hospital Contracts
Dubai Healthcare City hosts several specialty compounding pharmacies operating under DHA-DHCC dual licensing. DHCC compounding pharmacies serve both individual patient prescriptions through in-zone specialist clinics and institutional contracts with DHCC hospitals and medical centres. DHCC zone fees for pharmacy space run AED 150–350 per square foot per year. The high concentration of specialist physicians in DHCC—reproductive medicine, oncology, dermatology, and ophthalmology—creates organic demand for customised compounded preparations that commercial pharmaceutical products cannot efficiently address.
Hospital compounding contract models—where a standalone compounding pharmacy supplies patient-specific sterile preparations, parenteral nutrition, and oncology admixtures to one or more hospitals under a formal supply agreement—are legally permitted in the UAE provided the compounding is genuinely patient-specific and the hospital has a valid compounding supply agreement reviewed by DHA or DOH. Batch manufacturing without patient-specific prescriptions is considered pharmaceutical manufacturing and requires a full MOHAP pharmaceutical manufacturing licence rather than a compounding pharmacy licence. Compounding pharmacies operating hospital contracts must ensure all preparations are dispensed against individual patient prescriptions to avoid reclassification as a manufacturer.
| Regulatory Item | Authority | Fee / Cost (AED) | Cycle |
|---|---|---|---|
| Compounding Pharmacy Licence (Northern Emirates) | MOHAP | 15,000–40,000 | Annual |
| DHA Compounding Permit (Dubai) | DHA | 10,000–25,000 | Annual |
| DOH Compounding Endorsement (Abu Dhabi) | DOH | 12,000–28,000 | Annual |
| Controlled Substances API Import Permit | MOHAP | 1,500–5,000 per batch | Per shipment |
| Sterile Compounding Suite Construction | N/A (capital cost) | 300,000–800,000 | One-time |
| Pharmacist-in-Charge Registration | DHA / MOHAP | 2,000–5,000 | Annual |
Frequently Asked Questions
What is the difference between a compounding pharmacy and a pharmaceutical manufacturer in the UAE?
A compounding pharmacy prepares patient-specific customised medications against individual prescriptions, while a pharmaceutical manufacturer produces commercial drug products in batches for general market distribution. The regulatory distinction is critical in the UAE: batch production without patient-specific prescriptions requires a full MOHAP pharmaceutical manufacturing licence, not a compounding pharmacy licence. Compounding pharmacies operating hospital supply contracts must ensure all preparations are dispensed against individual patient prescriptions to remain within compounding licence boundaries.
How many pharmacists are required for a UAE compounding pharmacy?
MOHAP and DHA both require a minimum of two licensed pharmacists, one of whom must be formally designated and registered as the Pharmacist-in-Charge (PIC). The PIC bears regulatory responsibility for all compounding activities, quality standards, controlled substances management, and staff training. For sterile compounding, all pharmacists must additionally pass annual aseptic technique and media-fill competency assessments.
What cleanroom standard is required for sterile compounding in the UAE?
MOHAP and DHA reference USP Chapter 797 (2023 revision) as the applicable standard. Sterile compounding requires an ISO 5 primary engineering control (laminar flow hood or isolator) located within an ISO 7 buffer room. Facilities handling hazardous drugs (USP 800) additionally require negative-pressure ISO 7 containment buffer rooms and appropriate primary engineering controls such as CACI or Class II B2 biosafety cabinets.
Can bulk APIs be freely imported for UAE compounding pharmacies?
No. All APIs must be pharmaceutical-grade and sourced from MOHAP-registered suppliers. Import requires MOHAP Drug Control Department authorisation: a general API import permit for non-controlled substances and a separate MOHAP Controlled Substances Import Permit per batch for opioids, benzodiazepines, and other scheduled substances. MOHAP inspectors verify API sourcing records during facility inspections and may confiscate materials from unregistered sources.
Is hospital supply contracting permitted for UAE compounding pharmacies?
Yes, with regulatory safeguards. Standalone compounding pharmacies may supply hospitals under formal compounding supply agreements reviewed by DHA or DOH, provided all preparations are dispensed against individual patient prescriptions. DHCC compounding pharmacies operate several such hospital contracts. Pharmacies that produce non-prescription-specific batches for hospital stock are considered pharmaceutical manufacturers and require a MOHAP pharmaceutical manufacturing licence rather than a compounding pharmacy licence.